Letters
“Breakthrough” drug in Alzheimer’s disease
Recent trial shows that solanezumab has disease modifying effects
BMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h4528 (Published 28 August 2015) Cite this as: BMJ 2015;351:h4528
- Eric Karran, director of research1
- 1Alzheimer’s Research UK, Cambridge CB21 6AD, UK
- k.marais{at}alzheimersresearchuk.org
McCartney raises important points about the media reporting of solanezumab but does not fully explore the data’s real importance.1
Current drugs for Alzheimer’s disease treat the symptoms only.2 Disease modifying drugs could reduce the numbers of people living with severe stage Alzheimer’s.3
The extension study (EXPEDITION-EXT) was designed to …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.